-transparent.png){kind=logo}
Intravenous finoptin (verapamil), 10 mg, was tested for effects on the coronary venous blood flow by probing the coronary sinus and great vein of the heart and performing atrial pacing in 24 patients with ischemic heart disease and eukinetic central hemodynamics. In persons who had had initial high blood flow in the coronary sinus, the agent was found to induce resting coronary venous blood flow changes which were inadequate for its demand and during cardiac pacing; whereas in patients with mean initial venous blood flow values, finoptin enabled myocardial oxygen consumption to be provided both in the region of non-infarcted myocardium and in the ischemic area.
Related Publications
L V Uchaĭkina, and
V D Vakhliaev
November 1996,
Zeitschrift fur Kardiologie,
L V Uchaĭkina, and
V D Vakhliaev
May 1995,
Vnitrni lekarstvi,
L V Uchaĭkina, and
V D Vakhliaev
May 2007,
Journal of applied physiology (Bethesda, Md. : 1985),
L V Uchaĭkina, and
V D Vakhliaev
September 1991,
Kardiologiia,
L V Uchaĭkina, and
V D Vakhliaev
March 1988,
Vrachebnoe delo,
L V Uchaĭkina, and
V D Vakhliaev
January 1982,
Terapevticheskii arkhiv,
L V Uchaĭkina, and
V D Vakhliaev
October 1982,
Der Anaesthesist,
L V Uchaĭkina, and
V D Vakhliaev
February 1992,
Kardiologiia,
L V Uchaĭkina, and
V D Vakhliaev
January 1982,
Biulleten' Vsesoiuznogo kardiologicheskogo nauchnogo tsentra AMN SSSR,
L V Uchaĭkina, and
V D Vakhliaev
January 1995,
Likars'ka sprava,
